Anti-Obesity Drug Linked To 5 Deaths In U.K.

Law360, New York (June 3, 2008, 12:00 AM EDT) -- Acomplia, the Sanofi-Aventis SA anti-obesity drug rejected by the U.S. Food and Drug Administration last year due to fears of psychiatric side effects, has been linked to five deaths, including one suicide, since it went on sale in the United Kingdom in 2006, new data show.

According to a report posted Tuesday on the Web site of the Medicines and Healthcare Products Regulatory Agency, the FDA's U.K. counterpart, 720 people in the U.K. reported adverse drug reactions from use of rimonabant, marketed in the U.K. as...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.